A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy
Phase 2
- Conditions
- Non small cell lung cancer10038666
- Registration Number
- NL-OMON31390
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
Histologically advanced NSCLC
Normal organ function
ECOG PS 0-2
Age >18 yrs
Measurable disease
Exclusion Criteria
History of cardiac disease
Symptomatic brain or leptomeningeal metastases
History of bleeding diasthesis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>No progression rate at 6 weeks</p><br>
- Secondary Outcome Measures
Name Time Method <p>Response rate, disease control rate, duration of response, time to progression<br /><br>or death, overall survival, safety.</p><br>